Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: The LEVEL study

British Journal of Ophthalmology

Volumn 94, Issue 12, 2010, Pages 1611-1617

  Friberg, Thomas R ^a   Tolentino, Michael ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Center for Retina and Macular Disease   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; PEGAPTANIB; RANIBIZUMAB;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BRAIN INFARCTION; BRONCHITIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONJUNCTIVA DISEASE; CONJUNCTIVAL HEMORRHAGE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE IRRITATION; EYE PAIN; FEMALE; GASTROESOPHAGEAL REFLUX; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATURIA; HUMAN; HYPERTENSION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPTICAL COHERENCE TOMOGRAPHY; PHASE 4 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PNEUMONIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PUNCTATE KERATITIS; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; RETINA NEOVASCULARIZATION; RETINA TEAR; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; TREATMENT RESPONSE; URINARY TRACT INFECTION; VISUAL ACUITY; VITREOUS FLOATERS; VITREOUS HEMORRHAGE; VITREOUS OPACITY;

AGED; ANGIOGENESIS INHIBITORS; APTAMERS, NUCLEOTIDE; CORNEA; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 78649858371     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.174946     Document Type: Article

References (25)

1. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
4. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007;41:614-25.
5. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-70.
6. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005;69(Suppl 3):25-33.
7. Tuñón J, Ruiz-Moreno JM, Martin-Ventura JL, et al. Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. Surv Ophthalmol 2009;54:339-48.
8. Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008;92:1606-11.
9. Marcus DM. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Four-year safety of pegaptanib sodium in neovascular age-related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Invest Ophthalmol Vis Sci 2008;49:E-abstract 5069.
10. Apte RS, Modi M, Masonson H, et al. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 2007;114:1702-12.
11. Hughes MS, Sang DN. Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2006;37:446-54.
12. Farah SE. Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed. Ophthalmic Surg Lasers Imaging 2008;39:294-8.
13. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171:53-67.
14. McLeod DS, Grebe R, Bhutto I, et al. Relationship between RPE and choriocapillaris in age-related macular degeneration. Invest Ophthalmol Vis Sci 2009;50:4982-91.
15. Peters S, Heiduschka P, Julien S, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007;143:995-1002.
16. Papadopoulou DN, Mendrinos E, Mangioris G, et al. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. Ophthalmology 2009;116:1755-61.
17. Uhlmann S, Friedrichs U, Eichler W, et al. Direct measurement of VEGF-induced nitric oxide production by choroidal endothelial cells. Microvasc Res 2001;62:179-89.
18. Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol 2006;147(Suppl 1):S193-201.
19. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007;7:475-85.
20. Bombeli T, Karsan A, Tait JF, et al. Apoptotic vascular endothelial cells become procoagulant. Blood 1997;89:2429-42.
21. Russell DA, Abbott CR, Gough MJ. Vascular endothelial growth factor is associated with histological instability of carotid plaques. Br J Surg 2008;95:576-81.
22. Gillies MC, Wong TY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2007;356:749-9; author reply 9-50.
23. Ueta T, Yanagi Y, Tamaki Y, et al. Cerebrovascular accidents in ranibizumab. Ophthalmology 2009;116:362.
24. Boyer DS, Heier JS, Brown DM, et al. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116:1731-9.
25. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.e1.